Profile
Andrew Satlin worked as the Director of Geriatric Psychiatry at McLean Hospital, Inc. from 1980 to 1997.
He then worked as the EVP & Global Head of Medicine Creation Strategy at Eisai, Inc. from 2008 to 2017.
After that, he served as the Chief Medical Officer & Executive Vice President at Intra-Cellular Therapies, Inc. from 2017 to 2020.
Prior to his work in the industry, he was an Assistant Professor at Harvard Medical School.
Satlin received his undergraduate degree from Yale University and his doctorate from Harvard Medical School.
Former positions of Andrew Satlin
| Companies | Position | End |
|---|---|---|
| INTRA-CELLULAR THERAPIES, INC. | Chief Tech/Sci/R&D Officer | 28/10/2020 |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Corporate Officer/Principal | 01/11/2017 |
McLean Hospital, Inc.
McLean Hospital, Inc. Hospital/Nursing ManagementHealth Services Provides healthcare services | Corporate Officer/Principal | 01/01/1997 |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Training of Andrew Satlin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Health Technology |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
McLean Hospital, Inc.
McLean Hospital, Inc. Hospital/Nursing ManagementHealth Services Provides healthcare services | Health Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat neuropsychiatric and neurological disorders | Health Technology |
- Stock Market
- Insiders
- Andrew Satlin
















